120
Views
6
CrossRef citations to date
0
Altmetric
Original Research

Exploring strategies to support medication adherence in patients with inflammatory arthritis: a patient-oriented qualitative study using an interactive focus group activity

, , , , , & show all
Pages 2015-2025 | Published online: 05 Oct 2018

Abstract

Objective

Medication non-adherence is a substantial problem among patients with inflammatory arthritis (IA). Our aim was to explore IA patients’ perspectives on strategies to support medication adherence.

Methods

We collaborated with a leading arthritis patient group and conducted a qualitative study on individuals with IA who were taking at least one medication for their IA. An experienced facilitator led participants through a focus group exercise where participants were asked to design, and then discuss, strategies and/or tools supporting medication use. We applied thematic analysis using an iterative, constant comparative approach.

Results

We studied six focus groups with 27 participants diagnosed with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and comparatively under-represented conditions in this research area such as Sjögren’s syndrome. Five themes emerged throughout the analysis. Two themes – 1) adapting to life with IA and 2) the complexities and dynamic nature of taking medications – describe learning to live with a chronic condition and the challenges encountered when using long-term medications. Three themes – 3) developing lifestyle strategies for medication use (eg, having physical reminders and prompts), 4) becoming informed about medications (eg, information at time of diagnosis, means of receiving information) and 5) receiving support (eg, from health care team members, from family) – offer perspectives on facilitators to medication use. From the relationship between the latter themes, a framework was developed that encompasses means of receiving information and support as actionable targets for patient-oriented adherence interventions for IA.

Conclusion

This patient-oriented study highlights the importance of developing timely adherence interventions for IA. Our findings also led to a framework describing means of receiving information, such as through digital media and support, including from health care team members and family, as actionable targets for patient-oriented adherence interventions for IA.

Video abstract

Point your SmartPhone at the code above. If you have a QR code reader the video abstract will appear. Or use:

http://youtu.be/nUywZmUXmW8

Introduction

Long-term pharmacotherapy is paramount to the successful management of inflammatory arthritis (IA), as patients rely on medications to relieve symptoms, perform daily life activities and prevent irreversible joint and organ damage.Citation1 Systematic reviews synthesizing adherence rates as low as 10% in gout,Citation2 25% in systemic lupus erythematosus (SLE)Citation3 and 30% in rheumatoid arthritis (RA)Citation4 are alarming, given the association between non-adherence and adverse outcomes, including increased health care utilization,Citation5,Citation6 costsCitation7Citation9 and decreased ability to work.Citation10 Given this substantial burden of non-adherence among patients with IA, there is an urgent need for work in designing and evaluating interventions that promote and support treatment adherence. However, to date, such research has been disappointing, with less than half of published interventions reporting a significant impact on medication adherence or clinical outcomes.Citation11 These data support the importance of soliciting patient input to inform the development of successful adherence strategies and interventions.

Patient-oriented research, defined as meaningful and active collaboration in priority setting, conducting and translating research,Citation12 may provide an ideal opportunity to address the burden of non-adherence in IA. To illuminate practical strategies and solutions that may be operationalized into effective adherence interventions through a patient-centered lens, we conducted a patient-oriented qualitative study in partnership with a leading national arthritis patient group based in British Columbia (BC), Canada. Our objective was to explore IA patients’ perspectives on tools and strategies to support chronic medication use using an interactive focus group activity.

Methods

Patient partnership

We partnered with the Arthritis Patient Advisory Board (APAB) of Arthritis Research Canada, a leading national consumer group of individuals living with IA who regularly collaborate in arthritis research.Citation13 As we describe in further detail below, APAB members were engaged throughout the research process, including grant preparation (with one member appointed as a co-investigator on the study team), participant recruitment, focus group activity design and refinement, data analysis and interpretation and manuscript writing.

Study sample

Eligible participants were those who met the following criteria: 1) rheumatologist-confirmed diagnosis of IA, 2) 19 years of age or older, 3) currently taking medication (eg, disease modifying anti-rheumatic drugs [DMARD]) for their IA and 4) able to communicate in English. Participants were recruited from rheumatology clinics in the lower mainland of BC. APAB supported study recruitment through their various social media channels, including their quarterly electronic newsletter, members’ Twitter feeds and word-of-mouth advertising. Although we originally intended to include only patients with RA, APAB members recommended including a broader range of inflammatory arthritis, given that many conditions share similar treatments, and to ensure capture of rarer conditions that were less represented in prior qualitative research of medication use. As such, we purposively sampled participants on age, sex, type and duration of IA diagnosis and IA medication(s) prescribed to obtain diverse perspectives and experiences.

Study design and methodology

We used a qualitative approach for data gathering, specifically focus group methodology, as processes and interactions within focus groups more readily facilitate people’s exploration and clarification of views than one-on-one interviews and can enhance the depth and breadth of the information obtained.Citation14,Citation15 We used a relatively novel technique of incorporating a group activity to focus the attention of the group on the core topic of the study.Citation16 Specifically, a trained facilitator asked participants to describe or design at least one strategy and/or tool (whether hypothetical or currently available) that would support their medication use on color-coded labels and corresponding activity sheets provided. Participants were then invited to share their strategies/tools with the group and the facilitator used open-ended questions to promote discussion. To allow sufficient time for the activity and subsequent discussion, focus groups were formed with four to six participants. Each focus group interaction lasted approximately two hours and was audio recorded and transcribed verbatim for analysis. At least one study team member attended all focus group interactions as an observer, noting elements of participants’ actions and interactions. APAB inputs for the focus group design included providing feedback on the topic guide to ensure the use of appropriate and accessible language that would effectively engage participants; furthermore, we conducted a pilot focus group interaction with six APAB members to identify areas for improvement in execution of the group activity. The uses of color-coded labels and activity sheets were a direct result of this pilot focus group with APAB, as we had originally proposed the uses of poster boards and cards attached with velcro, which were found cumbersome and potentially challenging for the target patient population.

Data analysis

Analysis of the focus group data was guided by thematic analysis informed by aspects of grounded theoryCitation17 and used an iterative, constant comparative approach.Citation18 The first step in this approach was open coding, whereby each line of the transcript was ascribed individual codes that represented its main concept or phenomenon. This was an iterative process, since information from previous decisions helped to inform subsequent ones and vice versa. Constant comparison helped to identify patterns and similarities between data from different transcripts and notes were made to help inform subsequent steps in the analysis. The second step was axial coding, where codes were condensed and sorted; similar phenomena were grouped together and relationships between codes were explored and mapped. Finally, selective coding resulted in a final list of five higher-level themes and associated categories that captured the main ideas discussed by participants in relation to their experiences with the disease and medication use. This list was reviewed in relation to existing literature and theories on this topic and additional themes or categories were added. All six transcripts were subsequently reviewed and recoded according to these themes. Furthermore, APAB members provided input on study results during interim and final presentations on elucidated themes.

Results

We held six focus group interactions with a total of 27 participants, including 17 women and 10 men. As shown in , our sampling strategy achieved a broad representation of diagnoses, including RA, psoriatic arthritis (PsA) and ankylosing spondylitis (AS), as well as comparatively underrepresented conditions in this research area (eg, Sjögren’s syndrome and granulomatosis with polyangiitis). Nine participants had been living with IA for 5 years or less and 18 participants for over 5 years. also shows current IA medications taken by participants; methotrexate was the most common medication taken by participants (n=15), either alone or in combination with another DMARD. A total of 13 participants were taking biologic therapy.

Table 1 Characteristics of focus group participants

Five themes emerged from the analyses. The first two themes of 1) adapting to life with IA and 2) the complexities and dynamic nature of taking medications described the interrelated experiences of living with and taking medications for IA, with illustrative quotes for each theme and category provided in . Then three overlapping and interlocking themes of 3) developing lifestyle strategies for medication use, 4) becoming informed about medications and 5) receiving support collectively capture participants’ perspectives on facilitators to medication use, as illustrated in quotes in .

Table 2 Illustrative quotes for themes on living with and taking medications for inflammatory arthritis

Table 3 Illustrative quotes for themes on strategies and supports for medication use in inflammatory arthritis

Theme 1: Adapting to life with inflammatory arthritis

The theme of adapting to life with IA was captured in four categories: 1) being diagnosed, 2) losing identity, 3) accepting the disease and 4) experiencing personal, social and career impacts. At the outset of each focus group interaction, participants detailed receiving their diagnosis, including struggling to deal with their diagnoses and searching for reasons for the onset of their condition – “I mean why did this happen to me? Is it genetic? Is it something that I ate?” (RA, methotrexate). Many also described the adjustment – both initially from being a healthy individual to having a diagnosis and the associated loss of identity, as well as with respect to long-term acceptance of living with a chronic condition. Through these, participants touched on “…big restrictions…” (RA, gold) imposed on them by their diseases, with impacts on families: “I’ve got a young kid and another one coming. So it’s tough for me to do things at home with them” (AS, etanercept), on friendships: “…I think I’ve lost friends over it…” (RA, gold) and on careers: “[Doctor] had said a while ago to apply for disability and I didn’t want to. I wanted to keep working” (AS, adult-onset Still’s disease, methotrexate, sulfasalazine, etanercept).

Theme 2: Complexities and dynamic nature of taking medications for inflammatory arthritis

Intertwined with participants’ experiences of their IA diagnoses were their experiences with medications, which were summed across six categories as complex and dynamic: “Every single drug they tried me on I have either a physical reaction or worse. So it’s been a very long frustrating journey” (RA, gold). Four categories – 1) taking medications, 2) trying different medications, 3) being able to afford medications/accessing expensive medications and 4) experiencing unwanted effects of medications – capture the challenges experienced by participants in taking medications for their IA. For example, the first category included issues on managing multiple medications and administering medications, particularly the use of needles with the sentiment “…I hate needles…” (AS, hydroxychloroquine, golimumab) echoed across focus groups. Being able to afford medications or the process of accessing medications (particularly biologics) was also identified as a challenge, as well as experiencing unwanted side effects of medications such as injection site inflammation, allergic reactions, nausea, infections and complications associated with other organs (eg, neurological complications) and worrying about long-term effects of chronic medication use. The fifth category, not taking medications, captures both intentional – “…I was very anti-drug. So when I was diagnosed, I was actually given a prescription for methotrexate, which I did not use” (RA, SjS, cyclosporine, adalimumab) – and non-intentional – “Because if I’m out with friends or if I’m really tired after a long week, I will forget” (RA, hydroxychloroquine, methotrexate, tocilizumab) reasons why participants did not take IA medications. Finally, despite challenges, we also identified a sixth category of feeling better with medications and how medications had positively impacted their IA: “It’s like a cloud has been lifted and I can function” (PsA, methotrexate, adalimumab).

Theme 3: Developing lifestyle strategies for medication use

The third theme captures lifestyle strategies, both already implemented and suggested, by participants that support medication use. Consistent across focus groups was making a routine of taking medication, for example, at the same time each day or each week, or combining it with other daily activities that can serve as a reminder: “make that medicine so much part of your life that you do not think about it. It’s like eating.” (RA, methotrexate, rituximab). Facilitating the development of routines was planning ahead, for example, injecting methotrexate on weekends and having medications on hand at all times, as well as having physical reminders and prompts, such as placing medications with routine household items (eg, beside a toothbrush). Organizational tools such as blister packs obtained from pharmacies as well as pill cases were also found to be useful, along with calendars.

Theme 4: Becoming informed about medications

In the fourth theme, participants discussed various aspects of becoming informed about IA medications across three categories of: 1) receiving information at the time of diagnosis, 2) information needs and 3) means of receiving information. Participants touched on the importance of receiving sufficient information about medication at the time of IA diagnosis which some felt was lacking when they were diagnosed. Various information needs were captured in the second category including how to take the medication, side effects, as well as how the medication works and placing an emphasis on its importance: “I think the big one is impressing on a lot of people how important it is to take your medication and that missing a dose can be pretty disastrous for some people” (PsA, etanercept). Hearing about other patients’ experiences of living with IA and using prescribed medications was viewed mostly positively: “…and then from people who experience it. Just say, ‘Hey this is my experience and, you know, how it could progress. You can do this” (AS, hydroxychloroquine, golimumab). In addition to their own information needs, some felt that education of family members would also be helpful:

And if I could add I think the education of your spouse or caregiver to know that having the medications needed to be done pretty well at the same time is going to make it easier for you to be able to make the commitments for social activities and things and for that to be part of the education process. It helps to just keep the whole thing on course, right? (RA, methotrexate, sulfasalazine).

Aside from the type of information, participants also emphasized the importance of being able to recognize whether information was credible or trustworthy; this was particularly important for information collected from the Internet. The final category identified means of receiving information about medications, including group classes, written resources and in particular, digital technologies.

Theme 5: Receiving support

This theme describes a number of means by which patients receive support, including functional and emotional, from individuals such as health care providers and family members as well as other tangible supports. The first category captures the importance of education from participants’ health care providers, including rheumatologists and nurses as well as pharmacists. However, participants also noted challenges with health encounters, particularly the need for more time, especially when explaining their conditions and medications. The second category captures the importance of support from family, whether it is reminding participants to take their medications or helping administer medications. The third category captures the role of digital technologies in supporting medication use. Participants identified two main technologies – the Internet and smartphones – that they used, as well as anticipate other patients with IA using. Health apps were also discussed and within this subcategory participants described desired features and functions of medication taking apps, such as setting more detailed reminders for multiple medications (eg, including dosage information), cataloging information about missed or altered doses, recording side effects and synchronizing with the pharmacy and insurance company. Finally, within the fourth category, some participants also noted other supports, including patient support programs provided by drug companies for the use of biologics:

I was set up with, well not a nurse but the drug company themselves. And they did everything for me from the special authority, like chasing down [my rheumatologist] to help to see if they processed it (AS, hydroxychloroquine, golimumab).

Relationship between themes

From our analyses, there are two essential considerations for adherence – information (as captured in Theme 4) and support (as captured in Theme 5) and we outline a framework for patient-oriented adherence interventions for IA. In the framework shown in , actionable targets for adherence interventions for IA represent potential areas for designing patient-oriented adherence interventions. These areas may be in the form of receiving support as captured by Theme 5. For example, an adherence intervention may be designed to facilitate encounters with health care team members to optimize patient support. Another target area for an adherence intervention for IA is through means of receiving support as captured by Theme 4, category 3. With this, an adherence intervention may be designed around arthritis group classes, written resources, or digital technologies as means to deliver information. Outside of the actionable targets but also key to this framework is Theme 4’s category 1 of “information needs” which represents inputs for these actionable targets in terms of patient-identified knowledge gaps that could be readily addressed by the interventions.

Figure 1 Framework for patient-oriented adherence interventions for inflammatory arthritis based on relationship between study themes on becoming informed about medications (Theme 4) and receiving support (Theme 5).

Figure 1 Framework for patient-oriented adherence interventions for inflammatory arthritis based on relationship between study themes on becoming informed about medications (Theme 4) and receiving support (Theme 5).

Discussion

We conducted a patient-oriented qualitative study using an interactive focus group activity to better understand IA patients’ perspectives on and experiences with chronic medication use. Findings of this study conducted in partnership with a national arthritis consumer group include participant accounts of the complexities and dynamic nature of living with and taking medications for IA. Our study also confirms the importance of having information and receiving support as key facilitators of taking medication and has expanded on these with categories describing when information should be delivered, what type of information is needed and the means of receiving information. Aside from identifying individuals who provide functional and emotional support (eg, health care team and family members), participants also identified other tangible supports for medication use including digital technologies. Taking these together lends itself to a framework for patient-oriented adherence interventions for IA that encompasses means of receiving information and support as actionable targets for patient-oriented adherence interventions for IA.

Aside from confirming recommendations, including those from the European League Against Rheumatism on patient education for people with IA as priority care,Citation19 our finding on the importance of becoming informed about medications supports results from our prior systematic review of medication adherence interventions in IA, that those shown to have an impact on adherence outcomes included an educational component.Citation11 Perhaps more valuable, the current qualitative study identifies tangible areas for education development drawn directly from patients with IA such as when information should be delivered (ie, at the time of diagnosis) and what information is desired. With respect to the latter, our findings suggest that educational tools that effectively present how to take medications, how medications work, including potential benefits in addition to the risks may be helpful to individuals with IA. Furthermore, patients with IA emphasized the need for information to be drawn from the experiences of other patients, which has been echoed in studies in RACitation20 and SLECitation21 populations. For example, utilizing other patients’ experiences may help to alleviate apprehensions about medication side effects, as identified in prior studies.Citation22,Citation23 Lastly, patient preferences for information delivery extended beyond the typical health care setting to patient groups, written resources and digital technologies, thereby highlighting future avenues for intervention development. Such informational tools and resources may be further bolstered by behavioral strategies that support daily medication use. Indeed, participants in the current study described specific strategies used to overcome the daily logistical challenges encountered with long-term medication use.

Study participants with IA indicated multiple opportunities to optimize medication adherence through functional and/or emotional support, namely by means of health care professionals, family and digital technologies. Indeed, the important role of health care providers in supporting medication use has been shown in recent qualitative syntheses among patients with RA,Citation20 systemic autoimmune rheumatic diseases,Citation24 and gout.Citation25 Importantly, our study adds a collective perspective from IA patients, including those living with less common forms of IA, on some of the challenges with health care providers, including the need for more time during encounters as well as improved communication, particularly when multiple providers are involved in a patient’s care. Also, similar to prior qualitative inquiry in IA,Citation22,Citation23 our focus groups articulated how family can provide reminders and assist with administering injections, all while having a deeper insight into the personal experiences and needs of the individual with IA. Aside from identifying the supporting role of family members, participants in our study also identified the need for information to be delivered to family members themselves.

In terms of other tangible supports, study participants identified the role of digital technologies which have indeed gained traction in supporting care in rheumatology, with implications for medication use.Citation26 With health apps forming a sub-category within this theme, participants identified a number of desired features such as the ability to organize medications or serve as a means to communicate a patient’s medication taking to their rheumatologist or pharmacist. Indeed, the ubiquitous and accessible nature of digital technologies makes for potential adherence support tools. However, there remains need for work in this area. We conducted a scoping review and quality assessment and identified 704 smartphone medication adherence apps in Apple and Android platforms and noted that the primary function of the majority of apps was sending a reminder or alert to users to take their medication.Citation27 Apps specific to rheumatic diseases, such as SLECitation28 and RA,Citation29 however focus on monitoring disease activity rather than medication use. As such, subsequent directions to optimize medication adherence may include building apps specific to IA that incorporate patient preferences such as dynamic follow-up after the initial dose reminder, access to reliable drug information and synchronization with pharmacies and insurance companies.

Strengths and limitations

The strengths of our study deserve comment. Unique to our study is the patient-oriented approach used to explore medication use among individuals with IA. Engaging APAB, a renowned arthritis patient organization in Canada, throughout the research enriched the execution of this study, including input on the use of patient-friendly language in the topic guide, opportunity to pilot and refine the focus group and embedded activity, as well as providing a “patient lens” to the interpretation and reporting of the findings. Further, strengthening our study is the use of focus groups, as group processes and interactions more readily facilitate participants’ exploration and clarification of views and opinions as compared with one-on-one interviews, thereby enhancing the depth and breadth of the information obtained.Citation14,Citation15 Next, while the majority of focus group participants were individuals with RA, we were additionally able to recruit individuals with less common forms of IA that have generally been underrepresented in prior qualitative research in this area. Moreover, our findings across these patient populations suggest largely shared experiences and perspectives on the topic, thereby broadening the applicability of our findings.

Nevertheless, potential limitations of our study also warrant discussion. Participant recruitment primarily took place in the metropolitan city of Vancouver; however, those living in rural communities in BC were also invited to participate through phone or videoconference, thereby broadening the representation of our sample and increasing the generalizability of our findings. Next, those who voluntarily participated in our study may be more likely to use their medications as prescribed and thus might not reflect the perspectives of “non-adherent” individuals. However, this is an inherent limitation of all voluntary research studies and is not limited to the current study.

Conclusion

This patient-oriented qualitative study conducted in the Canadian province of BC has enriched our understanding of the complexities of medication use in IA. Beyond confirming the roles of information and support as facilitators of medication use, we have established a framework that identifies practical and actionable targets for patient-oriented adherence interventions for IA.

Data availability

The datasets generated and/or analyzed during the current study are not publicly available as they contain information that could compromise participant privacy. Nevertheless, these data are available from the corresponding author on reasonable request.

Ethical approval

Ethics approval was obtained from the Behavioral Research Ethics Board at the University of British Columbia (protocol #H14-01460). All participants provided written informed consent.

Author contributions

All authors meet the conditions for authorship according to the IMCJE guidelines. All authors contributed toward data analysis, drafting and critically revising the paper and agree to be accountable for all aspects of the work.

Acknowledgments

This study was funded by the Canadian Rheumatology Association (CRA)’s Canadian Initiative for Outcomes in Rheumatology Care (CIORA) grant program. The study sponsor had no role in the study design, data collection, analysis/interpretation, writing of the manuscript and decision to submit the manuscript for publication. Dr De Vera holds a Canada Research Chair in Medication Adherence, Utilization and Outcomes and is a recipient of a Network Scholar Award from The Arthritis Society/Canadian Arthritis Network and a Scholar Award from the Michael Smith Foundation for Health Research. We gratefully acknowledge members of Arthritis Research Canada’s Patient Advisory Board for their contributions to the design and execution of the study.

Disclosure

The authors report no conflicts of interest in this work.

References

  • CampbellNKJSaadeldinKDe VeraMAThe Duality of Economic Issues With Medication Non-adherence in Patients With Inflammatory ArthritisCurr Rheumatol Rep201719106628921409
  • De VeraMAMarcotteGRaiSGaloJSBholeVMedication adherence in gout: a systematic reviewArthritis Care Res2014661015511559
  • MehatPAtiquzzamanMEsdaileJMAviña-ZubietaADe VeraMAMedication Nonadherence in Systemic Lupus Erythematosus: A Systematic ReviewArthritis Care Res2017691117061713
  • SaltEFrazierSKAdherence to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a narrative review of the literatureOrthop Nurs201029426027520664466
  • FeldmanCHYazdanyJGuanHSolomonDHCostenbaderKHMedication Nonadherence Is Associated With Increased Subsequent Acute Care Utilization Among Medicaid Beneficiaries With Systemic Lupus ErythematosusArthritis Care Res2015671217121721
  • JulianLJYelinEYazdanyJDepression, medication adherence, and service utilization in systemic lupus erythematosusArthritis Rheum200961224024619177526
  • BorahBJHuangXZarotskyVGlobeDTrends in RA patients’ adherence to subcutaneous anti-TNF therapies and costsCurr Med Res Opin20092561365137719425902
  • PasmaASchenkCTimmanRDoes non-adherence to DMARDs influence hospital-related healthcare costs for early arthritis in the first year of treatment?PLoS One2017122e017107028152001
  • HalpernRModyRRFuldeoreMJPatelPAMikulsTRImpact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysisCurr Med Res Opin20092571711171919485724
  • PavelkaKForejtovaSStolfaJAnti-TNF therapy of ankylosing spondylitis in clinical practice. Results from the Czech national registry ATTRAClin Exp Rheumatol200927695896320149312
  • GaloJSMehatPRaiSKAvina-ZubietaADe VeraMAWhat are the effects of medication adherence interventions in rheumatic diseases: a systematic reviewAnn Rheum Dis201675466767325667208
  • Canadian Institutes of Health ResearchStrategy for Patient-Oriented Research2017 Available from: http://www.cihr-irsc.gc.ca/e/41204.htmlAccessedDecember 15, 2017
  • LeeseJKerrSMckinnonAEvolving Patient-Researcher Collaboration: An Illustrative Case Study of a Patient-Led Knowledge Translation EventJ Particip Med201791e13
  • KitzingerJQualitative research. Introducing focus groupsBMJ199531170002993027633241
  • KitzingerJThe methodology of Focus Groups: the importance of interaction between research participantsSociol Health Illn1994161103121
  • ColucciE“Focus groups can be fun”: the use of activity-oriented questions in focus group discussionsQual Health Res200717101422143318000081
  • BraunVClarkeVUsing thematic analysis in psychologyQual Res Psychol20063277101
  • BoeijeHA purposeful approach to the constant comparative method in the analysis of qualitative interviewsQual Quant2002364391409
  • ZangiHANdosiMAdamsJEULAR recommendations for patient education for people with inflammatory arthritisAnn Rheum Dis201574695496225735643
  • KellyATymmsKTunnicliffeDJPatients’ Attitudes and Experiences of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis and Spondyloarthritis: A Qualitative SynthesisArthritis Care Res2018704525532
  • SutantoBSingh-GrewalDMcNeilHPExperiences and perspectives of adults living with systemic lupus erythematosus: thematic synthesis of qualitative studiesArthritis Care Res2013651117521765
  • BrandstetterSHertigSLossJEhrensteinBApfelbacherC‘The lesser of two evils…’ – views of persons with rheumatoid arthritis on medication adherence: a qualitative studyPsychol Health201631667569226832226
  • VoshaarMVriezekolkJvan DulmenSvan den BemtBvan de LaarMBarriers and facilitators to disease-modifying antirheumatic drug use in patients with inflammatory rheumatic diseases: a qualitative theory-based studyBMC Musculoskelet Disord201617144227769224
  • HaagHLiangTAvina-ZubietaJAde veraMAHow do patients with systemic autoimmune rheumatic disease perceive the use of their medications: a systematic review and thematic synthesis of qualitative researchBMC Rheumatology2018219
  • RaiSKChoiHKChoiSHJKey barriers to gout care: a systematic review and thematic synthesis of qualitative studiesRheumatology201857712821292
  • DixonWGMichaudKUsing technology to support clinical care and research in rheumatoid arthritisCurr Opin Rheumatol201830327628129369089
  • LiJTsaoNCampbellNDe VeraMASmartphone Medication Adherence Mobile Apps: A Scoping Review and Quality AssessmentVancouver, BC, CanadaUniversity of British Columbia Multidisciplinary Undergraduate Research Conference2018
  • PourrahmatMZusmanEZDe VeraMAPatient-targeted smartphone apps for systemic lupus erythematosus: A systematic review and assessment of feature and qualityAmsterdam, NetherlandsEuropean League Against Rheumatism Annual European Congress of Rheumatology2018
  • GraingerRTownsleyHWhiteBLanglotzTTaylorWJApps for People With Rheumatoid Arthritis to Monitor Their Disease Activity: A Review of Apps for Best Practice and QualityJMIR Mhealth Uhealth201752e728223263